Igor Gorbatchevsky

706 total citations
36 papers, 512 citations indexed

About

Igor Gorbatchevsky is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Igor Gorbatchevsky has authored 36 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Genetics and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Igor Gorbatchevsky's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (16 papers) and Advanced Breast Cancer Therapies (10 papers). Igor Gorbatchevsky is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (16 papers) and Advanced Breast Cancer Therapies (10 papers). Igor Gorbatchevsky collaborates with scholars based in United States, France and United Kingdom. Igor Gorbatchevsky's co-authors include Pier Luigi Zinzani, Florian Hiemeyer, David Cunningham, Kim Linton, Franck Morschhauser, Umberto Vitolo, Li Liu, Marius Giurescu, J. Garcia‐Vargas and G. Verhoef and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Igor Gorbatchevsky

35 papers receiving 500 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Igor Gorbatchevsky United States	9	291	242	207	159	93	36	512
Giulia Cervetti Italy	14	341 1.2×	252 1.0×	265 1.3×	63 0.4×	105 1.1×	37	615
Evgenii A. Osmanov Russia	6	352 1.2×	316 1.3×	207 1.0×	110 0.7×	42 0.5×	22	493
Helle Toldbod Denmark	9	513 1.8×	405 1.7×	145 0.7×	191 1.2×	89 1.0×	13	804
Alma María Rodríguez United States	5	344 1.2×	286 1.2×	208 1.0×	215 1.4×	53 0.6×	7	597
Yuqin Song China	10	231 0.8×	206 0.9×	202 1.0×	111 0.7×	19 0.2×	65	443
Nadine Juge‐Morineau France	12	250 0.9×	266 1.1×	149 0.7×	162 1.0×	22 0.2×	18	553
Jesse G. Dixon United States	9	323 1.1×	276 1.1×	145 0.7×	68 0.4×	104 1.1×	22	502
Jiří Mayer Czechia	7	309 1.1×	249 1.0×	153 0.7×	76 0.5×	57 0.6×	14	386
A J Bucur Germany	5	295 1.0×	259 1.1×	173 0.8×	105 0.7×	17 0.2×	6	461

Countries citing papers authored by Igor Gorbatchevsky

Since Specialization

Citations

This map shows the geographic impact of Igor Gorbatchevsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor Gorbatchevsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor Gorbatchevsky more than expected).

Fields of papers citing papers by Igor Gorbatchevsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Igor Gorbatchevsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor Gorbatchevsky. The network helps show where Igor Gorbatchevsky may publish in the future.

Co-authorship network of co-authors of Igor Gorbatchevsky

This figure shows the co-authorship network connecting the top 25 collaborators of Igor Gorbatchevsky. A scholar is included among the top collaborators of Igor Gorbatchevsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Igor Gorbatchevsky. Igor Gorbatchevsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Curigliano, G., Massimo Cristofanilli, S-B. Kim, et al.. (2025). LBA17 Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1. Annals of Oncology. 36. S1562–S1563. 1 indexed citations

Wesolowski, Robert, Hope S. Rugo, Jennifer M. Specht, et al.. (2025). Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer. Clinical Cancer Research. 31(19). 4040–4048.

André, Fabrice, Massimo Cristofanilli, Giuseppe Curigliano, et al.. (2024). Abstract PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1). Cancer Research. 84(9_Supplement). PO2–20. 1 indexed citations

Layman, Rachel M., Hyo S. Han, Hope S. Rugo, et al.. (2024). Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. The Lancet Oncology. 25(4). 474–487. 31 indexed citations

Rugo, Hope S., Robert Wesolowski, Erica Stringer-Reasor, et al.. (2023). 204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients. ESMO Open. 8(1). 101393–101393. 1 indexed citations

Hurvitz, Sara A., Fabrice André, Massimo Cristofanilli, et al.. (2023). Abstract CT063: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1). Cancer Research. 83(8_Supplement). CT063–CT063. 2 indexed citations

Layman, Rachel M., Robert Wesolowski, Hyo S. Han, et al.. (2022). Abstract PD13-02: Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer. Cancer Research. 82(4_Supplement). PD13–2. 8 indexed citations

Soumerai, Jacob D., Deepa Jagadeesh, Izidore S. Lossos, et al.. (2021). Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.. Journal of Clinical Oncology. 39(15_suppl). 7553–7553. 1 indexed citations

Jurczak, Wojciech, Pier Luigi Zinzani, David Cunningham, et al.. (2021). Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL).. Journal of Clinical Oncology. 39(15_suppl). TPS7573–TPS7573. 2 indexed citations

10.

Lenz, Georg, Eliza A. Hawkes, Gregor Verhoef, et al.. (2020). Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 34(8). 2184–2197. 52 indexed citations

11.

Sarnaik, Amod, Brendan D. Curti, Diwakar Davar, et al.. (2018). A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.. Journal of Clinical Oncology. 36(15_suppl). TPS9595–TPS9595. 2 indexed citations

12.

Haigentz, Missak, et al.. (2018). A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.. Journal of Clinical Oncology. 36(15_suppl). TPS3107–TPS3107. 2 indexed citations

13.

Morschhauser, Franck, Krimo Bouabdallah, Dominique Bron, et al.. (2017). Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Annals of Oncology. 28(9). 2169–2178. 192 indexed citations

14.

Lenz, Georg, Eliza A. Hawkes, Gregor Verhoef, et al.. (2017). Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 35(15_suppl). 7536–7536. 12 indexed citations

15.

Nowakowski, Grzegorz S., Igor Gorbatchevsky, Florian Hiemeyer, Lisa Cupit, & Barrett H. Childs. (2016). Abstract CT084: A randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL): CHRONOS-2. Cancer Research. 76(14_Supplement). CT084–CT084. 1 indexed citations

16.

Pettengell, Ruth, Bertrand Coiffier, Geetha Narayanan, et al.. (2012). Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. The Lancet Oncology. 13(7). 696–706. 88 indexed citations

17.

Feldman, Darren R., Lawrence H. Einhorn, David I. Quinn, et al.. (2011). A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs).. Journal of Clinical Oncology. 29(15_suppl). 4638–4638. 2 indexed citations

18.

Pettengell, Ruth, Geetha Narayanan, Raghunadharao Digumarti, et al.. (2009). Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology. 27(15_suppl). 8523–8523. 8 indexed citations

19.

Herbrecht, Raoul, Stephen Couban, Florian Weißinger, Igor Gorbatchevsky, & Richard H. van der Jagt. (2007). CHOP-R (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab) Compared to CPOP-R (Cyclophosphamide, Pixantrone, Vincristine, Prednisone, Rituxamib) in First-Line Therapy of Diffuse Large B Cell Lymphoma (DLBCL): An Interim Analysis.. Blood. 110(11). 3445–3445. 6 indexed citations

20.

Engert, Andreas, Raoul Herbrecht, Armando Santoro, Pier Luigi Zinzani, & Igor Gorbatchevsky. (2006). EXTEND PIX301: A Phase III Randomized Trial of Pixantrone Versus Other Chemotherapeutic Agents as Third-Line Monotherapy in Patients with Relapsed, Aggressive Non-Hodgkin's Lymphoma. Clinical Lymphoma & Myeloma. 7(2). 152–154. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact